Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient`s blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
Website: qualigeninc.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 50.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -200.0%. On average the margin is decreasing steadily. Gross margin is normal, +23.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 75% of quarters (showing a gain of +$0.25 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -507.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 13.1% higher than minimum and 98.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -6.4x by EV / Sales multiple

Key Financials (Download financials)

Ticker: QLGN
Share price, USD:  (0.0%)0.4
year average price 0.8076  


year start price 0.9251 2023-03-31

max close price 1.2100 2023-08-03

min close price 0.3537 2024-03-19

current price 0.4000 2024-03-29
Common stocks: 3 944 404

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  50.0%
Historical growth of EBITDA:  ---
EV / Sales: -0.9x
Margin (EBITDA LTM / Revenue): -200.0%
Fundamental value created in LTM:
Market Cap ($m): 2
Net Debt ($m): -7
EV (Enterprise Value): -5
Price to Book: -1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol QLGN QLGN QLGN QLGN QLGN QLGN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-14 2023-08-14 2023-05-15 2023-05-02 2022-11-14 2022-08-15
acceptedDate 2023-11-14 16:54:20 2023-08-14 16:16:09 2023-05-15 16:06:27 2023-05-02 16:26:02 2022-11-14 16:53:47 2022-08-15 16:17:49
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 2M 2M 1M 1M 1M
costOfRevenue 0 1M 1M 1M 1M 1M
grossProfit 0 610 489 342 342 293 726 163 036 330 857
grossProfitRatio 0 0.375 0.213 0.211 0.113 0.231
researchAndDevelopmentExpenses 1M 1M 2M 2M 2M 2M
generalAndAdministrativeExpenses 1M 3M 2M 3M 3M 3M
sellingAndMarketingExpenses 0 169 223 199 114 267 129 239 865 305 103
sellingGeneralAndAdministrativeExpenses 1M 3M 2M 3M 3M 3M
otherExpenses 33 454 5680.000 4881.000 330.000 0 0
operatingExpenses 3M 4M 4M 5M 5M 4M
costAndExpenses 3M 5M 5M 6M 6M 6M
interestIncome 0 760 416 0 -15 764 4631.000 4824.000
interestExpense 367 257 377 416 544 236 7M 4631.000 -19 248
depreciationAndAmortization -239 090 122 787 121 184 109 993 -231 751 77 017
ebitda -3M -4M -4M 51 643 -5M -4M
ebitdaratio 0 -2.339 -2.222 0.037 -3.202 -2.841
operatingIncome -3M -4M -4M -58 350 -4M -4M
operatingIncomeRatio 0 -2.183 -2.298 -0.042 -3.041 -2.895
totalOtherIncomeExpensesNet -89 405 382 672 -578 269 -9M 327 070 19 248
incomeBeforeTax -3M -4M -4M -9M -4M -4M
incomeBeforeTaxRatio 0 -2.179 -2.657 -6.333 -2.814 -2.881
incomeTaxExpense 421 512 -38 182 -163 777 -271 247 -230 767 5438.000
netIncome -4M -3M -4M -9M -4M -4M
netIncomeRatio 0 -2.129 -2.556 -6.138 -2.654 -2.885
eps -0.720 -0.690 -0.830 -2.220 -0.970 -1.130
epsdiluted -0.720 -0.690 -0.830 -2.220 -0.970 -1.130
weightedAverageShsOut 5M 5M 5M 4M 4M 4M
weightedAverageShsOutDil 5M 5M 5M 4M 4M 4M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol QLGN QLGN QLGN QLGN QLGN QLGN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-14 2023-08-14 2023-05-15 2023-05-02 2022-11-14 2022-08-15
acceptedDate 2023-11-14 16:54:20 2023-08-14 16:16:09 2023-05-15 16:06:27 2023-05-02 16:26:02 2022-11-14 16:53:47 2022-08-15 16:17:49
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 2M 1M 4M 7M 7M 10M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 2M 1M 4M 7M 7M 10M
netReceivables 235 402 679 380 411 104 538 587 603 291 719 883
inventory -235 402 2M 1M 2M 1M 1M
otherCurrentAssets 1M 11 636 12 161 2M 2M 2M
totalCurrentAssets 3M 5M 8M 11M 10M 14M
propertyPlantEquipmentNet 0 2M 2M 2M 2M 2M
goodwill 0 625 602 625 602 625 602 5M 5M
intangibleAssets 0 6M 6M 6M 6M 6M
goodwillAndIntangibleAssets 0 6M 6M 6M 11M 11M
longTermInvestments 0 5434.000 0 0 0 0
taxAssets 0 -5434.000 0 0 0 0
otherNonCurrentAssets 866 481 23 768 23 920 24 024 23 958 24 052
totalNonCurrentAssets 866 481 8M 8M 8M 13M 13M
otherAssets 0 0 -1.000 0 0 0
totalAssets 4M 13M 16M 19M 23M 26M
accountPayables 2M 2M 899 948 857 311 596 039 918 327
shortTermDebt 832 100 2M 2M 1M 1M 1M
taxPayables 0 37 328 27 618 32 194 27 041 24 823
deferredRevenue 1M 94 474 112 902 116 161 102 640 109 833
otherCurrentLiabilities 2M 5M 5M 6M 3M 4M
totalCurrentLiabilities 6M 8M 8M 9M 5M 6M
longTermDebt 0 1M 1M 1M 1M 1M
deferredRevenueNonCurrent 0 28 648 40 712 49 056 60 521 70 814
deferredTaxLiabilitiesNonCurrent 0 150 369 192 587 357 757 736 000 736 000
otherNonCurrentLiabilities 0 0 1.000 0 323 667 87 104
totalNonCurrentLiabilities 0 1M 1M 2M 2M 2M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 0 1M 1M 2M 2M 2M
totalLiabilities 6M 10M 10M 10M 7M 8M
preferredStock 0 0 0 0 0 0
commonStock 42 952 42 952 42 952 42 110 42 110 38 795
retainedEarnings -114M -111M -107M -103M -97M -93M
accumulatedOtherComprehensiveIncomeLoss 0 131 891 170 444 50 721 154 063 65 540
othertotalStockholdersEquity 113M 113M 112M 111M 109M 108M
totalStockholdersEquity -2M 2M 5M 7M 12M 14M
totalEquity -2M 3M 6M 7M 12M 14M
totalLiabilitiesAndStockholdersEquity 4M 13M 16M 19M 23M 26M
minorityInterest 0 1M 1M 2M 0 0
totalLiabilitiesAndTotalEquity 4M 13M 16M 19M 23M 26M
totalInvestments 0 5434.000 0 0 0 0
totalDebt 832 100 3M 3M 3M 3M 3M
netDebt -1M 2M -1M -4M -4M -7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol QLGN QLGN QLGN QLGN QLGN QLGN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-14 2023-08-14 2023-05-15 2023-05-02 2022-11-14 2022-08-15
acceptedDate 2023-11-14 16:54:20 2023-08-14 16:16:09 2023-05-15 16:06:27 2023-05-02 16:26:02 2022-11-14 16:53:47 2022-08-15 16:17:49
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -2M -4M -4M -9M -4M -4M
depreciationAndAmortization -239 090 122 787 116 303 109 993 89 549 91 817
deferredIncomeTax -150 369 -410 664 -165 170 0 0 0
stockBasedCompensation 122 696 653 919 252 226 1M 1M 1M
changeInWorkingCapital 141 376 -40 857 654 975 521 108 -495 381 -1M
accountsReceivables 0 -255 259 246 645 214 011 -46 504 -65 941
inventory 0 -108 769 71 379 -199 347 -200 133 110 978
accountsPayables 52 516 856 616 43 137 261 116 -322 454 -83 243
otherWorkingCapital 88 860 -533 445 293 814 245 328 73 710 -1M
otherNonCashItems 3M 254 181 614 822 4M -129 813 -22 445
netCashProvidedByOperatingActivities 929 739 -3M -3M -2M -3M -4M
investmentsInPropertyPlantAndEquipment 246 418 -48 409 -198 009 -244 374 -11 260 -13 858
acquisitionsNet 0 0 0 -135 354 0 135 354
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 4M 0 0 135 354 0 0
netCashUsedForInvestingActivites 4M -48 409 -198 009 -244 374 -11 260 121 496
debtRepayment -440 000 0 0 0 0 0
commonStockIssued 0 0 0 -2M 0 2M
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 0 5M 3314.000 -2M
netCashUsedProvidedByFinancingActivities -440 000 -1.000 1.000 3M 3314.000 1.000
effectOfForexChangesOnCash -115 803 -44 517 160 320 -4884.000 61 751 -34 228
netChangeInCash 726 756 -3M -3M 416 358 -3M -4M
cashAtEndOfPeriod 2M 1M 4M 7M 7M 10M
cashAtBeginningOfPeriod 1M 4M 7M 7M 10M 14M
operatingCashFlow 929 739 -3M -3M -2M -3M -4M
capitalExpenditure 246 418 -48 409 -198 009 -244 374 -11 260 -13 858
freeCashFlow 1M -3M -3M -2M -3M -4M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2023-11-14 00:00 ET
Qualigen Therapeutics reported for 2023 q3
SEC form 8
2023-08-15 00:00 ET
Qualigen Therapeutics reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Qualigen Therapeutics reported for 2023 q2
SEC form 10
2023-05-15 00:00 ET
Qualigen Therapeutics reported for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Qualigen Therapeutics reported for 2022 q4
SEC form 6
2023-03-31 16:05 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2023-02-13 09:30 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2023-01-20 16:30 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2023-01-10 16:15 ET
Qualigen Therapeutics published news for 2022 q4
SEC form 6
2022-12-22 16:15 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-12-12 09:01 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-11-22 09:10 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 10
2022-11-14 16:53 ET
Qualigen Therapeutics reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Qualigen Therapeutics reported for 2022 q3
SEC form 6
2022-10-28 17:03 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-10-26 09:00 ET
Qualigen Therapeutics published news for 2022 q3
SEC form 6
2022-09-02 07:00 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-26 16:15 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-16 06:20 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 8
2022-08-16 00:00 ET
Qualigen Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 16:17 ET
Qualigen Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Qualigen Therapeutics reported for 2022 q2
SEC form 6
2022-08-04 16:17 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-08-04 16:16 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-07-13 06:15 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-07-01 16:15 ET
Qualigen Therapeutics published news for 2022 q2
SEC form 6
2022-06-22 16:55 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 6
2022-06-15 16:05 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 6
2022-06-02 09:10 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 10
2022-05-13 06:10 ET
Qualigen Therapeutics reported for 2022 q1
SEC form 6
2022-05-13 06:05 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 8
2022-05-13 00:00 ET
Qualigen Therapeutics reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
Qualigen Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 6
2022-04-29 16:52 ET
Qualigen Therapeutics published news for 2022 q1
SEC form 10
2022-03-31 16:06 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 17:18 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 6
2022-01-18 09:30 ET
Qualigen Therapeutics published news for 2021 q4
SEC form 6
2021-12-17 06:15 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 13:09 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 6
2021-12-09 17:25 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 6
2021-12-01 15:39 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 10
2021-11-15 09:00 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Qualigen Therapeutics published news for 2021 q3
SEC form 10
2021-08-16 16:16 ET
Qualigen Therapeutics published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Qualigen Therapeutics published news for 2021 q2
SEC form 6
2021-08-13 16:05 ET
Qualigen Therapeutics published news for 2021 q2
SEC form 6
2021-05-17 17:21 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-05-17 16:23 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 10
2021-05-14 13:01 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 10
2021-05-14 00:00 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 15:16 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-04-09 16:10 ET
Qualigen Therapeutics published news for 2021 q1
SEC form 6
2021-03-31 16:33 ET
Qualigen Therapeutics published news for 2020 q4
SEC form 6
2021-03-05 09:15 ET
Qualigen Therapeutics published news for 2020 q4
SEC form 6
2021-01-06 16:18 ET
Qualigen Therapeutics published news for 2020 q4
SEC form 6
2020-12-18 15:54 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-12-08 09:30 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 16:32 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 10
2020-11-12 17:14 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-11-03 16:15 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-10-09 16:15 ET
Qualigen Therapeutics published news for 2020 q3
SEC form 6
2020-10-02 16:43 ET
Qualigen Therapeutics published news for 2020 q3